Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666565 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL200488 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7354978 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7360612 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL7354973 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL22370881 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL20973808 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL19582680 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| Alcohol SCHEMBL7359179 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| Butane SCHEMBL28217400 | 0.90 | CA12 (0.46) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116656634-A | Dioxygenase mutant and application thereof in synthesis of (2S, 3R) -3-hydroxy piperidine acid | 江南大学 | 2023-08-29 | — | — | CN | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120230724-A | L-proline hydroxylase and application of engineering enzyme thereof in substrate hydroxylation | 常州合全药业有限公司 | 2025-07-01 | — | — | CN | disclosed |
| WO-2024175024-A1 | NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| WO-2024151638-A2 | COMPOUNDS FOR FGFRS INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2005000305-A1 | 3-AMINOPIPERIDINES AND 3-AMINOQUINUCLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-5922703-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0720617-B1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | PROCTER & GAMBLE (US) | 1998-12-30 | — | — | EP | disclosed |
| CN-1135221-A | Urethane-containing aminosteroid compounds | PROCTER & GAMBLE (US) | 1996-11-06 | — | — | CN | disclosed |
| EP-0720617-A1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008559-A1 | NOVEL URETHANE-CONTAINING AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | CA12 4876/4885CA1 4814/4885CA2 4593/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | CA12 4599/4885CA1 3830/4885CA2 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.